INTERCEPT PHARMACEUTICALS IN (ICPT) Stock News

USA - NASDAQ:ICPT - US45845P1084 - Common Stock

19 USD

+0.04 (+0.21%)

Last: 11/7/2023, 8:02:20 PM

19 USD

0 (0%)

After Hours: 11/7/2023, 8:02:20 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ICPT Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Intercept Pharmaceuticals, Inc.

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

2 years ago - By: Benzinga - Mentions: GILD CBAY

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

2 years ago - By: Intercept Pharmaceuticals, Inc.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

2 years ago - By: Benzinga - Mentions: HSTM NXGN OLK GPCR

Top 5 Health Care Stocks That Should Keep You Up At Night

2 years ago - By: The Motley Fool

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

2 years ago - By: InvestorPlace

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

2 years ago - By: InvestorPlace - Mentions: NXGN SPLK CHS PKOH ...

Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now

2 years ago - By: Kahn Swick & Foti, LLC

INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT

2 years ago - By: Seeking Alpha

Intercept stock drops amid report from European Medicines Agency on Ocaliva (NASDAQ:ICPT)

2 years ago - By: The Motley Fool - Mentions: CBAY

Why CymaBay Therapeutics Stock Is Jumping Today

2 years ago - By: Brodsky & Smith LLC - Mentions: SPLK AMTI NXGN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –

2 years ago - By: Seeking Alpha

Intercept failed NASH candidate precipitated Alfasigma acquisition

2 years ago - By: Kahn Swick & Foti, LLC

INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT

2 years ago - By: Seeking Alpha

Canaccord cuts Intercept to hold, calls Alfasigma deal

2 years ago - By: Seeking Alpha

Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say

2 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma

2 years ago - By: Brodsky & Smith LLC - Mentions: SPLK AMTI NXGN CSCO ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –

2 years ago - By: Halper Sadeh LLC

ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders

2 years ago - By: Intercept Pharmaceuticals, Inc.

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases